Skip to main
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna is setting itself up for future success with its diverse portfolio of clinical-stage programs, particularly the recent release of positive Phase 1 data for SEP-631 in the treatment of chronic spontaneous urticaria (CSU). With a planned Phase 2b trial for SEP-631 in the second half of 2026 and a promising TSHR negative allosteric modulator (NAM) program in development for the treatment of Graves' disease and thyroid eye disease, Septerna's prospects look strong. Though conservative, with a projected price objective of $35 per share, there are potential risks to consider such as delays in clinical development, setbacks in trials, and partnership risks with Novo Nordisk.

Bears say

Septerna is currently in a phase of discovery and development with its GPCR oral small molecule drug discovery platform. While it has a diverse pipeline of product candidates targeting various therapeutic areas, the company's ongoing activities and partnerships do not provide a strong indication of future success or profitability. As such, the company's financial outlook is concerning and may not justify investing in the stock.

Septerna Inc (SEPN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.